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Background: To compare prospectively the diagnostic efﬁcacies for 
determining TNM stages of integrated PET/CT and 3T whole-body MR 
imaging (WB MRI) in non-small cell lung cancer (NSCLC).
Methods: Our study included 155 patients (M: F = 120:35, mean; 
61 ± 11 years) with pathologically proven NSCLC who underwent 
both integrated PET/CT and WB MRI. After acquiring dedicated lung 
images (breath-hold triple inversion black blood [TIBB] T2W turbo 
spin-echo [TSE] and T1W Turbo-ﬁeld echo [TFE] images), WB MRI 
(composed of 8 stacks of coronal images) was performed by using 
T2W TSE and pre- and post-contrast enhanced T1W TFE sequences. 
At PET/CT, abnormal uptakes were regarded present when suspected 
lesions demonstrated discrete FDG uptake at a level greater than that of 
surrounding tissues. At MRI, nodes showing high-signal intensity with 
eccentric cortical thickening or obliterated fatty hilum on T2W images 
were considered malignant. Discrete lesions with high signal intensity 
on T2W TSE images were considered metastatic, if they demonstrated 
signiﬁcant enhancement on T1W TFE images. Pathology for T (n = 
125) and N (n = 142) stage determination, and pathology or follow-up 
imaging studies (n = 149) for M staging served as reference standards. 
Findings: Primary tumor (n = 125) was correctly staged in 99 patients 
(79%) at PET/CT and in 103 patients (82%) at WB MRI (p = 0.572, 
the McNemar test). N stage (n = 142) was correctly determined in 98 
(69%) patients at PET/CT and in another 98 (69%) at WB MRI (p = 
1.000). Fourteen (M1, 9%) of 149 patients had 23 metastatic lesions. 
Accuracy for detecting metastases was 93% (138 of 149) at PET/CT, 
whereas that at WB MRI was 95% (142 of 149) (p = 0.388). WB MRI 
was more useful for detecting brain metastases, whereas PET/CT for 
soft-tissue metastases.
Interpretation: Both 3T WB MRI and PET/CT appear to provide ac-
ceptable accuracy and comparable efﬁcacy in NSCLC staging, but in 
M stage determination, they have different advantages from each other. 
Therefore, whole body MR/PET may be the future imaging modality 
for NSCLC staging.
C2-07 Staging Eﬃcacy, Wed, 10:30 - 12:15
A phase III clinical trial to evaluate the measurement of tumor 
proliferation using [18F]Fluoro-3’ deoxy-3’-L-fluorothymidine 
(FLT) positron emission tomography in patients with lung cancer 
Ryu, Jin-Sook1 Oh, Seung Jun1 Im, Ki-Chun2 Kim, Euy-Nyong1 Park, 
Seung Il1 Kim, Dong Kwan1 Kim, Yong Hee1 Chang, Se Jin1 Cho, 
Young Mee1 Lee, Hyun Seung2 Moon, Dae Hyuk 
1 Asan Medical Center, University of Ulsan College of Medicine, Seoul, 
Korea 2 Asan Medical Center, Seoul, Korea 
Background: This study was performed to validate the efﬁcacy of 
FLT-positron emission tomography (PET) as a noninvasive tumor 
proliferation imaging method and the safety of FLT as a diagnostic 
radiopharmaceutical. 
Methods: A prospective, nonrandomized, phase III clinical trial was 
performed in a single center. Adult (>18 yr) patient(pt)s with primary 
lung cancer with > 1.5 cm in size, scheduled to surgery after staging 
work-up were eligible. Before surgery, FLT-PET images of chest ﬁeld 
were obtained using a PET/CT scanner at 1 hr after injection of 370 
MBq FLT. Standardized uptake values (SUV) of tumor were measured 
using a threshold (80% of maxSUV) deﬁned volume of interest. After 
surgery, Ki-67 values of tumor were measured by two pathologists who 
were blind to FLT-PET results. The primary endpoint of this study was 
a good correlation between the measurements of tumor proliferation by 
SUVs using FLT-PET and Ki-67 values (H0; ρ ≤ 0.5 vs H1; ρ > 0.5, 
p < 0.05). In a statistical consideration, the necessary sample size was 
88 pts, and we enrolled total of 110 pts considering possible 20% drop 
rate. The secondary endpoint was no severe adverse reaction related to 
FLT, which was monitored before and after administration of FLT. 
Results: Among 110 pts, data form 93 pts were analyzed after exclu-
sion of 17 pts due to various reasons according to the protocol (techni-
cally inadequate images, inadequate surgical specimen, pt withdrawal, 
protocol violation, etc.). The tumor proliferation measured by FLT-PET 
was correlated well with Ki-67 values. The correlation coefﬁcient(ρ) 
between SUVs using FLT-PET and Ki-67 values was 0.6416, and it was 
signiﬁcantly greater than 0.5 (p<0.05). In subgroup analyses, ρ was 
0.7305 (p<0.05) in tumors ≤ 3 cm in size, while it was 0.4570 (p>0.05) 
in tumors > 3 cm in size. In all 110 pts, 10 mild or moderate adverse 
reactions were recorded, but no reaction was considered to be related to 
FLT and all pts recovered. 
Conclusions: FLT-PET is an effective and safe imaging method to 
measure tumor proliferation in vivo.
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Background: Erlotinib is an inhibitor of epidermal growth factor re-
ceptor tyrosine kinase (EGFR-TK) approved for treatment of refractory 
non-small cell lung cancer (NSCLC). Preclinical studies indicate that 
EGFR-TK inhibitors enhance the effects of ionizing radiation. We per-
formed this Phase I trial to determine the maximum tolerated dose of 
erlotinib that can be administered with two standard chemoradiotherapy 
approaches for NSCLC. 
Methods: Patients with unresectable stage III NSCLC were en-
rolled in this 2-arm dose-escalation study. Arm A (SWOG 9504) 
included chemoradiotherapy with cisplatin(50mg/m2 IV d1,8,29,36), 
etoposide(50mg/m2 IV d1-5,29-33), chest radiation therapy (2Gy/
day, total 66Gy) and daily oral erlotinib for 7 weeks followed by 
docetaxel (75mg/m2 IV Q21d) for 3 cycles. Arm B (CALGB 39801) 
included induction paclitaxel (200mg/m2 d1) & carboplatin (AUC 6 
d1) for two 21-day cycles then chest radiation therapy with weekly 
paclitaxel(50mg/m2), weekly carboplatin (AUC=2) and daily erlotinib 
for 7 weeks. In both arms, the erlotinib dose was escalated from 50 to 
150mg/day in cohorts of 3-6 patients. Erlotinib was given only during 
concomitant chemoradiotherapy.
